Last reviewed
Mitochondrial Peptides Require Specialized Testing
SS-31 (Elamipretide) and MOTS-c are among the fastest-growing categories of research peptides submitted to ACS Peptide Testing Labs. These mitochondria-targeted peptides have unique structural features that require careful analytical approaches -- and our data shows they are frequently misrepresented by suppliers.
This guide covers what makes mitochondrial peptide testing different, what to look for in your results, and why independent verification is critical for this category.
SS-31 (Elamipretide): What You Need to Know
Peptide Profile
- Sequence: D-Arg-Dmt-Lys-Phe-NH2
- Molecular weight: 640.77 g/mol
- Formula: C32H49N7O5
- Key feature: Contains non-standard amino acid Dmt (2',6'-dimethyltyrosine)
- Mechanism: Selectively concentrates in the inner mitochondrial membrane via cardiolipin binding
Why SS-31 Testing Is Challenging
SS-31 contains D-amino acids and a non-standard amino acid (Dmt) that create unique analytical challenges:
- Stereochemistry matters: D-Arg must be confirmed as the D-enantiomer, not L-Arg. Standard RP-HPLC cannot distinguish enantiomers -- chiral chromatography or specialized methods are required.
- Dmt verification: 2',6'-dimethyltyrosine is not a standard amino acid. LC-MS/MS fragmentation must confirm the dimethyl substitution pattern.
- Small peptide challenges: At only 4 amino acids, SS-31 has fewer diagnostic fragments in MS/MS, making identity confirmation harder than for larger peptides.
- Amidation: The C-terminal amide (-NH2) must be verified, as the free acid form has different biological activity.
Our SS-31 Testing Data
From samples submitted to our lab:
- 68% of SS-31 samples show purity discrepancies vs. supplier claims
- Most common issue: Incorrect stereochemistry (L-Arg instead of D-Arg) found in 23% of samples
- Second most common: Missing or incomplete Dmt -- replaced with standard tyrosine in 15% of samples
- Average purity gap: 9.2 percentage points below claimed
Recommended SS-31 Testing Panel
- RP-HPLC purity analysis with optimized gradient for small peptides
- LC-MS identity confirmation (molecular weight verification)
- LC-MS/MS fragmentation for sequence and Dmt confirmation
- Chiral analysis to confirm D-Arg stereochemistry
- C-terminal amidation verification
MOTS-c: Testing Considerations
Peptide Profile
- Sequence: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg
- Molecular weight: 2174.56 g/mol
- Formula: C101H152N28O22S2
- Key feature: Mitochondrial-derived peptide containing two methionine residues susceptible to oxidation
Why MOTS-c Testing Is Different
- Methionine oxidation: MOTS-c contains two methionine residues (positions 1 and 6) that are highly susceptible to oxidation. Oxidized MOTS-c may have reduced biological activity but can appear pure on a basic HPLC chromatogram.
- Degradation during shipping: Improper temperature control during shipping frequently degrades MOTS-c. We see degradation products in approximately 30% of samples, often from poor handling rather than synthesis quality.
- Sequence complexity: At 16 amino acids with multiple basic residues, MOTS-c requires optimized chromatographic conditions to separate from truncated sequences.
Our MOTS-c Testing Data
- 71% of MOTS-c samples show measurable purity discrepancies
- Methionine oxidation detected in 34% of samples
- Truncated sequences found in 28% of samples
- Average purity gap: 8.7 percentage points below claimed
Recommended MOTS-c Testing Panel
- RP-HPLC purity analysis with methionine oxidation monitoring
- LC-MS identity confirmation
- LC-MS/MS full sequence verification
- Oxidation product quantification
- Stability assessment if samples arrived at room temperature
